Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Average Recommendation of “Buy” from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has earned an average recommendation of “Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $46.4286.

A number of equities analysts have recently commented on the stock. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently modified their holdings of AAPG. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $383,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter worth $391,000. XY Capital Ltd lifted its stake in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. Finally, UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter.

Ascentage Pharma Group International Trading Down 3.6%

AAPG stock opened at $18.68 on Wednesday. The stock has a 50-day simple moving average of $19.21 and a two-hundred day simple moving average of $23.11. Ascentage Pharma Group International has a twelve month low of $16.36 and a twelve month high of $48.45. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.